To leverage Medgene’s innovative vaccine platform technology, Elanco Animal Health Incorporated has entered into an agreement with the company to commercialise the highly pathogenic avian influenza (HPAI) vaccine for use in dairy cattle
Efforts by the poultry industry to reduce or irradiate HPAI spread have continued to be challenging as the current outbreak enters its fourth year. The cross-species and zoonotic transmission of the disease indicates the urgent need for intervention and calls for the development of a vaccine that can slow virus spread between birds and cattle.
“As egg prices soar and milk production wanes in infected dairies, the need for new solutions to curb disease spread is evident,” says Jeff Simmons, president and CEO of Elanco Animal Health, while expressing his pleasure to partner with Medgene. “This partnership further strengthens our diverse dairy portfolio and advances our One Health platform of animal health solutions, not only benefitting our dairy customers, but helping curb disease spread for our poultry customers, and working to improve egg prices for consumers.”